Comparative Pharmacology
Head-to-head clinical analysis: ALLI versus XENICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLI versus XENICAL.
ALLI vs XENICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces fat absorption by approximately 30%.
Reversible inhibitor of gastric and pancreatic lipases, preventing hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides.
60 mg orally three times daily with each main meal containing fat.
120 mg orally three times daily with each main meal containing fat (during or up to 1 hour after the meal). Omit dose if meal is skipped or contains no fat.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours for orlistat; however, the pharmacodynamic effect (fecal fat excretion) persists due to the drug's local action in the GI tract.
Clinical Note
moderateGallium nitrate + Digoxin
"Gallium nitrate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGallium nitrate + Digitoxin
"Gallium nitrate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGallium nitrate + Deslanoside
"Gallium nitrate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGallium nitrate + Acetyldigitoxin
"Gallium nitrate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 1-2 hours for the parent drug; clinically relevant as rapid clearance limits systemic exposure.
Fecal: approximately 97% (83% as unchanged drug, 4% as metabolites); Renal: less than 1%.
Primarily fecal (approximately 97% of absorbed dose), with less than 2% renal elimination as unchanged drug and metabolites.
Category C
Category C
Lipase Inhibitor
Lipase Inhibitor